Drugs / Lu AG09222
Lu AG09222
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT06578585 | Sep 2024 → Jul 2025 | migraine disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05304910 | Mar → Oct 2022 | migraine disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT05126316 | Nov 2021 → Jul 2022 | allergic rhinitis | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 1 | NCT04976309 | Jul → Sep 2021 | — | H. Lundbeck A/S | Completed | Met primary |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT06323928 | Apr 2024 → Jan 2026 | migraine disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 2 | NCT05133323 | Nov 2021 → Jan 2023 | migraine disorder | H. Lundbeck A/S | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| — | NCT02158221 Comparator | Jun → Nov 2014 | migraine without aura | Danish Headache Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | H. Lundbeck A/S | Results Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress lundbeck.com ↗
The results from the intravenous dosing part of the PROCEED trial reinforce previously reported positive topline findings and further support the therapeutic potential of targeting the PACAP pathway in prevention of severe migraine. |
| 2026-06-04 | H. Lundbeck A/S | Results Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting lundbeck.com ↗
Findings validate targeting PACAP for migraine prevention and support the |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | H. Lundbeck A/S | Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress lundbeck.com ↗ |
| 2026-06-04 | H. Lundbeck A/S | Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting lundbeck.com ↗ |
| 2021-11-19 | H. Lundbeck A/S | Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention lundbeck.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu AG09222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04976309 ↗ |
| Known as | PACAP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02158221 ↗ |
| Known as | Pituitary adenylate cyclase-activating polypeptide | “Pituitary adenylate cyclase-activating polypeptide (PACAP)” NCT02158221 ↗ |
| Action | Inhibit | “Lu AG09222 inhibited PACAP38-induced cephalic vasodilation and increases in heart rate, and reduced concomitant headache.” PMID 37231350 ↗ May 2023 |
| Modality | Peptide | “PACAP is a neuropeptide” NCT02158221 ↗ |
| Route | Intravenous | “PACAP intravenous infusion 1.5 microgram/min for 20 min” NCT02158221 ↗ |